



Investors Relations Presentation

Qatari German Medical Devices

Q2 2024

www.qgmd.com

Disclaimer

The following presentation is made only to, and is directed only at, persons to whom such a presentation may lawfully

be communicated (“relevant persons”). Any person who is not a relevant person should not act or rely on this

presentation or any of its contents.

This presentation contains forward-looking statements that are subject to risks and uncertainties,

including statements about QGMD’s beliefs and expectations.

These forward-looking statements are based on assumptions that QGMD has made in light of its experience in the industry in which it operates, as well as its perceptions of historical trends, current conditions, expected future

developments and other factors which QGMD believes are appropriate under the circumstances.

Prospective investors should understand that these statements are not guarantees of future performance or results.

Due to these factors, QGMD cautions that prospective investors should not place undue reliance on any

forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made.

New risks and uncertainties arise from time-to-time, and it is impossible to predict these events or how they may affect QGMD.





CONTENTS

- **Company Overview**
- **QGMD Production facilities & Machineries**
- **What we do?**
- **Financial Highlights**
- **Statement of Comprehensive Income**

COMPANY OVERVIEW



QG Medical Devices is one of the leading manufacturers of Medical Devices in the Middle East and the only Manufacturing Company producing syringes and IV cannulas in Qatar. Headquartered in Doha, Qatar.

QG Medical Devices Co. was established in the year 2000, with collaboration of a German Company to produce high quality medical devices in Qatar; utilizing best of breed technology and machines.

QG Medical Devices is a Public Listed Company in Qatar Stock Exchange.

QGMD PRODUCTION FACILITIES & MACHINERIES

QG Medical Devices is equipped with state of art production facility designed by reputable innovative technology providers from Germany, Switzerland and Italy.



WHAT WE DO?

QGMD is striving to become a leading medical devices manufacturer in the healthcare industry worldwide, as well as a strong partner in the medical trading and services industry; by continuing to introduce innovative and superior medical devices which guarantee better patient care.

- We strive :
- To introduce cutting edge solutions to the medical devices industry whereby Patient and Medical Staff Care are the core of our innovation
- To provide the international health community with safe, effective, and efficient medical devices of the highest quality.
- To reduce/eliminate (where possible) any potential risks associated with Medical industry .
- To guarantee a continued R&D and investment to produce innovative medical devices for the benefit of our patients and medical staff, and the community as a whole.
- To increase the trading and services lines by acquiring more medical partnership with local, regional and international agencies.
- QGMD is committed to develop innovative products that meet the requirements of the local and international market.



Q Ject® 1 ml Syringe



Manufacturing (Q JECT, Q SAFE, Q JECT
Ultra, Q FLOW, Q NEED)



Interim Condensed Financial Statements Review Report for the Six Months Ended June 30, 2024

Qatari German Medical Devices

JULY 31, 2024

www.qgmd.com

By : Amer Abu Shaikha - CEO



STATEMENT OF FINANCIAL POSITION AS AT June 30, 2024

	30 June 2024	31 December 2023
	(Reviewed)	(Audited)
	QR	QR
ASSETS		
Non-current assets		
Property, plant and equipment	102,376,689	104,615,821
Right-of-use asset	65,052	69,698
Investment property	12,484,000	12,484,000
Intangible assets	10,329,937	10,329,937
Total non-current assets	125,255,678	127,499,456
Current assets		
Inventories	24,637,923	24,729,200
Trade and other receivables	49,804,157	48,583,900
Cash and cash equivalents	389,059	119,892
Total current assets	74,831,139	73,432,992
TOTAL ASSETS	200,086,817	200,932,448
EQUITY AND LIABILITIES		
EQUITY		
Share capital	115,500,000	115,500,000
Legal reserve	30,807,629	30,807,629
Revaluation reserve	12,151,865	12,151,865
Accumulated losses	(121,563,358)	(122,425,204)
TOTAL EQUITY	36,896,136	36,034,290
LIABILITIES		
Non-current liabilities		
Borrowings	12,249,600	10,568,075
Provision for employees' end of service benefits	850,094	860,526
Lease liabilities	49,875	62,488
Total non-current liabilities	13,149,569	11,491,089
Current liabilities		
Borrowings	129,664,702	131,718,670
Trade and other payables	20,364,883	21,679,182
Lease liabilities	11,527	9,217
Total current liabilities	150,041,112	153,407,069
TOTAL LIABILITIES	163,190,681	164,898,158
TOTAL EQUITY AND LIABILITIES	200,086,817	200,932,448

		For the six-month period ended	
	Note	30 June 2024 (Reviewed) QR	30 June 2023 (Reviewed) QR
Revenue	15	7,546,327	24,988,593
Cost of revenue	16	(2,764,960)	(17,075,489)
Gross profit		4,781,367	7,913,104
Other income	17	1,405,104	1,275,057
Depreciation	18	(2,264,324)	(2,688,984)
Selling and distribution expenses		(150,276)	(329,201)
General and administrative expenses	19	(2,406,642)	(2,334,488)
Finance costs		(503,383)	(2,273,206)
Net profit for the period		861,846	1,562,282
Other comprehensive income		—	—
Total comprehensive income for the period		861,846	1,562,282
Basic Earnings Per Share	20	0.007	0.014



THANK YOU

Qatari German Medical Devices

www.qgmd.com